Dyslipidaemia in 2015: Advances in treatment of dyslipidaemia

Nat Rev Cardiol. 2016 Feb;13(2):74-5. doi: 10.1038/nrcardio.2015.208. Epub 2016 Jan 14.
No abstract available

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Anticholesteremic Agents / therapeutic use*
  • Azetidines / therapeutic use*
  • Biomarkers / blood
  • Cholesterol, LDL / blood
  • Cholesterol, LDL / drug effects*
  • Dyslipidemias / blood
  • Dyslipidemias / diagnosis
  • Dyslipidemias / drug therapy*
  • Glucuronides / therapeutic use*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Hyperlipoproteinemia Type II / drug therapy
  • Meta-Analysis as Topic
  • Proprotein Convertase 9
  • Proprotein Convertases / antagonists & inhibitors*
  • Randomized Controlled Trials as Topic
  • Serine Endopeptidases
  • Treatment Outcome

Substances

  • Anticholesteremic Agents
  • Azetidines
  • Biomarkers
  • Cholesterol, LDL
  • Glucuronides
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • ezetimibe glucuronide
  • PCSK9 protein, human
  • Proprotein Convertase 9
  • Proprotein Convertases
  • Serine Endopeptidases